Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

roval in the EU.

LIALDA/MEZAVANT for the treatment of diverticulitis

Phase 3 worldwide clinical trials investigating the use of the product for the treatment of diverticulitis were initiated in 2007 and are continuing.

SPD550 (Larazotide Acetate; also known as AT-1001) for the treatment of Celiac disease

SPD550 is being developed for the treatment of Celiac disease. In December 2007 Shire acquired the worldwide rights to SPD550 (Larazotide Acetate; also known as AT-1001) in markets outside of the US and Japan from Alba. The two parties have established Joint Committees which will guide the development, manufacture and commercialization of the product. Alba has initiated and is responsible for executing the ongoing Phase 2 program and certain non-clinical studies. Additional development studies may be conducted jointly or by the individual companies prior to or after initiation of Phase 3.

Treatments for diseases in other therapeutic areas

FOSRENOL for the treatment of pre-dialysis chronic kidney disease ('CKD')

Following the FDA Cardiovascular and Renal Drugs Advisory Committee recommendation in October of 2007 on the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in pre-dialysis CKD patients, Shire continues to work with the FDA to determine whether FOSRENOL can launch in the pre-dialysis CKD market in the US without conducting additional clinical outcomes trials.

JUVISTA

Renovo Limited ('Renovo') initiated its first pivotal European Phase 3 trial in scar revision in the fourth quarter of 2008 to support the filing of a European regulatory dossier. If the outcome from Renovo's multi centre, EU Phase 3 study is suitably positive, the data will be used to inform the strategy and design of Shire's US development plan and to strengthen the chances of regulatory and commercial success in the US.


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Texas Fertility Center ... in South Austin, expanding a Central Texas footprint that ... Antonio. The satellite office for the region’s most established ... to the South Austin, Buda, Kyle and San Marcos ... affordable fertility treatment directly to individuals and couples living ...
(Date:9/23/2014)... September 23, 2014 Marktech Optoelectronics has ... ultra violet emitters in the 280 nm wavelength range. ... emitters which range from 280nm to 405nm. These new ... sanitation as well as curing. Mark Campito, Marktech’s CEO ... special interest to manufacturers is that we offer it ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Williams ... third book on healthcare offers a three phase process ... century healthcare delivery system that would go far beyond ... responsibility regarding the delivery of healthcare.” , “Every effort ... has failed to provide discernable progress throughout that system ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... the globe will convene at the Society ... to be held October 26-28 in Houston, ... research and practice in individualized integrative cancer ... researchers, nurses, psychologists, nutritionists, naturopaths, acupuncturists, and ...
Breaking Biology Technology:Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Marktech Introduces its New Line of Deep UV Emitters 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... to grow over 23% per year due to new cellulite ... Millennium Research Group, WALTHAM, Mass., April 9, 2008 ... Devices 2008 report,the cellulite reduction device market was worth almost ... next five years, rising to over,$215 million by 2012. Growth ...
... Cytopia Limited,(ASX: CYT) today announced that it ... American Association for Cancer Research Annual Meeting being ... 17,000,participants from around the world to discuss new ... titled "A Novel JAK2 inhibitor for the treatment ...
... 2008 Dendreon Corporation,(Nasdaq: DNDN ) today ... direct offering of 8.0 million shares of its ... million shares of its common,stock. Net proceeds received ... LLC served as sole placement agent for the ...
Cached Biology Technology:Say Good-Bye to Cellulite 2Dendreon Announces Closing of Registered Direct Offering 2
(Date:9/23/2014)... organisms, including humans, have parasitic DNA fragments called "jumping ... instructions in the process. And that phenomenon can result ... the University of Rochester now report that the "jumping ... when a multi-function protein stops keeping them in check ... In a study published today in Nature Communications ...
(Date:9/22/2014)... Chicago have shown that after a long stay in ... pathogenic microbe species remain behind in patients, intestines. The ... can become deadly when provoked by conditions that mimic ... published in mBio , the online open-access journal ... better monitoring and treatment of ICU patients who can ...
(Date:9/22/2014)... September 23, 2014 A new American Cancer ... Nutrition Assistance Program (SNAP), previously known as the ... compared with income eligible non-participants. The authors say ... aimed at enhancing the dietary quality of SNAP ... low-income individuals and households with the resources to ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Federal food program puts food on the table, but dietary quality could be improved 2
... Santa Barbara have developed new methods for studying how environmental ... spatial and temporal scales. The scientists merged data collected ... canopies taken by the Landsat 5 Thematic Mapper. The findings ... issue of Marine Ecology Progress Series. In ...
... of State Foresters released the first phase of the Southern ... areas forest managers will focus on to maintain southern forests ... urbanization, bioenergy use, weather patterns, land ownership changes and invasive ... 2010 and 2060. About 23 million acres of forest ...
... is available in Spanish . The ... Ikerbasque, is participating in the AWIN -Animal Welfare Indicators project. ... international experts in animal welfare from 11 centres. The group ... University of Edinburgh on the 10 and 11 of May, ...
Cached Biology News:UCSB scientists track environmental influences on giant kelp with help from satellite data 2UCSB scientists track environmental influences on giant kelp with help from satellite data 3Forest Service unveils first comprehensive forecast on southern forests 2Forest Service unveils first comprehensive forecast on southern forests 3Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 2Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 3
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
CMRL Medium-1066 (1X) liquid...
... 11(R)-HETE is biosynthesized by the ... purpuratus, and the fresh water hydra, ... 11(R)-HETE relates to oocyte maturation and ... species.11(R)-HETE is also produced when aspirin-treated ...
... PhosphatidylEthanolamine-Binding Protein (PEBP) does not share ... inhibitors. PEBP is expressed in ... ovary, muscle, and stomach. One ... is exerting inhibitory activity against several ...
Biology Products: